OS Therapies Inc. Files 8-K

TL;DR

OS Therapies filed an 8-K on 9/30/25. No major news, just standard reporting.

AI Summary

OS Therapies Inc. filed an 8-K on September 30, 2025, reporting on other events and financial statements. The filing does not detail specific transactions or financial figures but serves as a notification of these items.

Why It Matters

This 8-K filing indicates that OS Therapies Inc. has submitted required disclosures to the SEC, which may contain updates on corporate events or financial performance.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for 'Other Events' and 'Financial Statements and Exhibits' without specific material disclosures, indicating low immediate risk.

Key Players & Entities

• OS Therapies Inc. (company) — Registrant
• September 30, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-42195 (identifier) — SEC File Number
• 82-5118368 (identifier) — IRS Employer Identification No.
• 115 Pullman Crossing Road , Suite 103 Grasonville , Maryland 21638 (address) — Address of Principal Executive Offices
• ( 410 ) 297-7793 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share OSTX NYSE American Indi

Filing Documents

• ea0259321-8k_ostherap.htm (8-K) — 27KB
• ea025932101ex5-1_ostherap.htm (EX-5.1) — 11KB
• ex5-1_001.jpg (GRAPHIC) — 21KB
• ex5-1_002.jpg (GRAPHIC) — 5KB
• 0001213900-25-093936.txt ( ) — 241KB
• ostx-20250930.xsd (EX-101.SCH) — 3KB
• ostx-20250930_lab.xml (EX-101.LAB) — 33KB
• ostx-20250930_pre.xml (EX-101.PRE) — 22KB
• ea0259321-8k_ostherap_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events. On September 30, 2025, OS Therapies Incorporated (the "Company") filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement (the "Prospectus Supplement"), which forms a part of the Company's registration statement on Form S-3 (File No. 333-289443), which was previously filed with the SEC on August 8, 2025 and declared effective on August 12, 2025. The Prospectus Supplement covers the resale from time to time of up to 4,373,043 shares of the Company's common stock (the "Shares") by the selling stockholders referenced in the Prospectus Supplement. The Company is filing this Current Report on Form 8-K to provide the legal opinion of its counsel, Olshan Frome Wolosky LLP, regarding the legality of Shares, which is attached hereto as Exhibit 5.1.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 5.1 Opinion of Olshan Frome Wolosky LLP. 23.1 Consent of Olshan Frome Wolosky LLP (included in its opinion filed as Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OS THERAPIES INCORPORATED Dated: September 30, 2025 By: /s/ Paul A. Romness, MPH Name: Paul A. Romness, MPH Title: President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR